Andrew Lockhart

Senior Vice President, Head Translational Disease Understanding at Grünenthal Group

Andrew Lockhart has extensive experience in the pharmaceutical industry, holding roles at companies such as Grünenthal Group, Sosei Heptares, GlaxoSmithKline, and Novartis. Andrew has served in leadership positions such as Senior Vice President and Programme Director, specializing in areas such as translational medicine and discovery medicine unit. Prior to their industry roles, they worked as a Postdoctoral Researcher at the Medical Research Council and the Marie Curie Research Institute, focusing on structural studies and protein chemistry.

Andrew Lockhart attended the University of Surrey from 1984 to 1988, earning a BSc in Biochemistry. Andrew then pursued a PhD in Protein Chemistry at Birkbeck, University of London from 1998 to 2001.

Links

Previous companies

Heptares Therapeutics logo
Novartis logo